A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7.

View in: PubMed

subject areas

Acute Disease
Acute Disease
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antithrombin III
Antithrombin III
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Double-Blind Method
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions
Drug-Related Side Effects and Adverse Reactions
Female
Female
Hemorrhage
Hemorrhage
Humans
Humans
Male
Male
Middle Aged
Middle Aged
Morpholines
Morpholines
Rivaroxaban
Rivaroxaban
Thiophenes
Thiophenes
Treatment Outcome
Treatment Outcome
Ultrasonography
Ultrasonography
Venous Thrombosis
Venous Thrombosis

authors with profiles

Gary E Raskob